Prostate Cancer

Top Story

Enzalutamide enhances PSA response, but not time to PSA progression, vs. abiraterone

June 28, 2017

CHICAGO – Enzalutamide demonstrated a greater PSA response among patients with metastatic, castration-resistant prostate cancer than abiraterone, although time to PSA progression was unchanged between the agents, according to a multicenter phase 2 crossover study presented at the ASCO Annual Meeting.

In addition, alterations in baseline pathogenic circulating tumor DNA, or ctDNA, including TP53 and BRCA2, were predictive of poor outcomes.

Family history of prostate cancer should not determine active surveillance eligibility

June 28, 2017
Family history did not appear associated with increased risk for aggressive disease among certain men with early prostate cancer, according to study results published in…
In the Journals Plus

Biomarkers may guide personalized therapy for castration-resistant prostate cancer

June 27, 2017
Assessment of androgen receptor gene status in plasma DNA identified patients with castration-resistant prostate cancer with worse outcomes to standard therapy…

Multimodal therapy eliminates detectable disease in early metastatic prostate cancer

June 27, 2017
Aggressive multimodal therapy appeared to eliminate all detectable disease among certain patients with early metastatic prostate cancer, according to study results…
CME

Immune Checkpoint Inhibitors for Advanced Bladder Cancer: Applying Clinical Advances and Elucidating Best Practices

This activity is supported by an educational grant from Merck & Co, Inc.

Advances in immunology and the advent of immune checkpoint blockade inhibition for advanced bladder cancer are poised…
More »
Video

VIDEO: Toxicities related to immune therapies ‘unpredictable’ but ‘manageable’

June 23, 2016
More »
Resource Centers

CME

Toward Precision Medicine for Advanced Melanoma Management: Making the Most of Targeted Agents

This activity is supported by an educational grant from Novartis.

The identification and utilization of melanoma specific biomarkers continues to be of importance for diagnosis and…
More »
Meeting News

Enzalutamide enhances PSA response, but not time to PSA progression, vs. abiraterone

June 28, 2017
CHICAGO – Enzalutamide demonstrated a greater PSA response among patients with metastatic, castration-resistant prostate cancer than…

Family history of prostate cancer should not determine active surveillance eligibility

June 28, 2017
Family history did not appear associated with increased risk for aggressive disease among certain men with early prostate cancer, according to study…

In the Journals Plus

Biomarkers may guide personalized therapy for castration-resistant prostate cancer

June 27, 2017
Assessment of androgen receptor gene status in plasma DNA identified patients with castration-resistant prostate cancer with worse outcomes to…

Multimodal therapy eliminates detectable disease in early metastatic prostate cancer

June 27, 2017
Aggressive multimodal therapy appeared to eliminate all detectable disease among certain patients with early metastatic prostate cancer, according to…

Biden Cancer Initiative seeks to inject urgency into cancer research, foster hope for patients

June 26, 2017
Former Vice President Joe Biden and his wife, Jill Biden, PhD, launched the Biden Cancer Initiative today. The venture is intended to further…

10 updates in immunotherapy research

June 23, 2017
In recognition of Cancer Immunotherapy Month, Cancer Research Institute has organized a series of educational and social events designed to raise…

Meeting News

Guest Commentary: STAMPEDE trial provides exciting results, questions in prostate cancer treatment

June 21, 2017
In this guest commentary, Terence Friedlander, MD, discusses the benefits associated with the addition of

Meeting NewsVideo

VIDEO: Results of LATITUDE trial reinforce long-hypothesized theory in prostate cancer treatment

June 21, 2017
CHICAGO — The results of the LATITUDE trial demonstrated that the addition of abiraterone acetate with prednisone to standard hormonal therapy…

Meeting NewsVideo

VIDEO: Immunotherapy agent induces response in prostate cancer

June 20, 2017
CHICAGO — The use of sipuleucel-T in patients with hormone-sensitive and castration-resistant prostate cancer demonstrated an increase in the…

Geneticist to lead Vanderbilt cancer center’s health disparities program

June 19, 2017
Tuya Pal, MD, has been appointed associate director of cancer health disparities at Vanderbilt-Ingram Cancer Center. Pal, a clinical geneticist…

More Headlines »
Advertisement
Advertisement